FIELD: biotechnology.
SUBSTANCE: disclosed are antibodies which specifically bind human CD38, pharmaceutical compositions and standard dosage forms containing said antibodies, as well as methods for preparing them. Also disclosed are methods of using antibodies to treat a disease associated with cells expressing CD38, for example, cancer.
EFFECT: invention provides more effective destruction of cells which express CD38, and more effective clinical response.
26 cl, 2 dwg, 19 tbl
Title | Year | Author | Number |
---|---|---|---|
COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
MOLECULES BINDING WITH CD38 AND PD-L1 | 2017 |
|
RU2764201C2 |
Therapeutic antibodies to CD47 | 2016 |
|
RU2748401C2 |
TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
ANTIBODIES SUITABLE FOR PASSIVE IMMUNIZATION AGAINST INFLUENZA, AND COMPOSITIONS THEREOF, COMBINATIONS AND METHODS OF USING | 2015 |
|
RU2720282C1 |
ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE | 2016 |
|
RU2815681C1 |
ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
TRISPECIFIC BINDING PROTEINS BINDING CD38, CD28 AND CD3, AS WELL AS METHODS OF USE FOR TREATING VIRAL INFECTION | 2019 |
|
RU2820351C2 |
STABLE MULTI-SPECIFIC ANTIBODIES | 2018 |
|
RU2779602C2 |
Authors
Dates
2024-09-19—Published
2020-04-23—Filed